The trial met its primary safety endpoint and showed durable, complete responses in intermediate-risk patients. Credit: Sai Thaw Kyar / Shutterstock.com. Johnson & Johnson (J&J) has reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results